title: Endophthalmitis is not a "never event".
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Schachat
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Rosenfeld
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Liesegang
authors.forename: Michael W
authors.initials: MW
authors.lastname: Stewart
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001419:Bacteria / Q000254:growth & development / Q000302:isolation & purification; D003228:Conjunctiva / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D009877:Endophthalmitis / Q000382:microbiology* / Q000517:prevention & control; D015818:Eye Infections, Bacterial / Q000382:microbiology* / Q000517:prevention & control; D006801:Humans; D058449:Intravitreal Injections / Q000009:adverse effects*; D009305:Nasopharynx / Q000382:microbiology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000900:Anti-Bacterial Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A